Since Bcl-2 family proteins are induced in the LN as a result of microenvironment-induced signaling, we hypothesized that ibrutinib treatment may interrupt those in vivo signals due to relocalization of CLL cells to the PB. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.